The Use of SLGT2 Inhibitors in the Treatment of Patients with Heart Failure

• Autor(a) principal: Grolla Matos, Letícia
• Data de Publicação: 2023
• Outros Autores: Neves da Costa , Alana, Teixeira Souza , Bianca, Negrini de Souza , Eduarda, Dardengo Gava , Fernanda, Pereira Peixoto , Sthephany, Oliveira Gil de Almeida , Yasmin, da Silva Gonçalves Junior , Wilson
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Brazilian Journal of Implantology and Health Sciences
• Texto Completo: https://bjihs.emnuvens.com.br/bjihs/article/view/1088
• topic: Insuficiência Cardíaca; Inibidores do SGLT2; Diabetes Mellitus

This article addresses the use of SGLT2 inhibitors in the treatment of heart failure. Objective: Patients with IC and diabetes mellitus (DM) had a reduction in hospitalizations for IC after using SGLT2, improved glycemic control and, consequently, improved health status. However, the biological mechanisms of SGLT2 in treating left ventricular ejection fraction are uncertain. Methods: Based on bibliographic research of articles with the descriptors "SGLT2" and "Heart Failure". Data were obtained without language limitations from MEDLINE via PubMed, Lilacs and SciELO. Results: Studies such as DECLARE-TIMI 5814, EMPEROR-REDUCED, DAPA-HF, CANVAS, EMPEROR-PRESERVED and DELIVER were found, whereby SGLT2 proved to be effective in reducing hospitalizations and cardiovascular deaths from HF, whether patients have or not from DM. Concomitantly, there was an improvement in symptoms, cardiac efficiency and cardiac subsidy. Conclusions: Studies on the mechanisms of SGLT2 are still needed, however, benefits are shown for HF associated or not with DM, providing a reduction in hospitalizations due to HF and cardiovascular mortality, an increase in quality of life and a better prognosis, with safety, good tolerance and low rate of adverse effects.